AI-ACCELERATED DRUG DISCOVERY

Focused On-demand Library for Phospholipase A2, membrane associated

Available from Reaxense
Predicted by Alphafold

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.

We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Our partner Reaxense helps in synthesizing and delivering these compounds.

Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.

Our top-notch dedicated system is used to design specialised libraries for enzymes.

 Fig. 1. The sreening workflow of Receptor.AI

This approach involves comprehensive molecular simulations of the catalytic and allosteric binding pockets and ensemble virtual screening that accounts for their conformational flexibility. In the case of designing modulators, the structural adjustments caused by reaction intermediates are considered to improve activity and selectivity.

Our library is unique due to several crucial aspects:

  • Receptor.AI compiles all relevant data on the target protein, such as past experimental results, literature findings, known ligands, and structural data, thereby enhancing the likelihood of focusing on the most significant compounds.
  • By utilizing advanced molecular simulations, the platform is adept at locating potential binding sites, rendering the compounds in the focused library well-suited for unearthing allosteric inhibitors and binders for hidden pockets.
  • The platform is supported by more than 50 highly specialized AI models, all of which have been rigorously tested and validated in diverse drug discovery and research programs. Its design emphasizes efficiency, reliability, and accuracy, crucial for producing focused libraries.
  • Receptor.AI extends beyond just creating focused libraries; it offers a complete spectrum of services and solutions during the preclinical drug discovery phase, with a success-dependent pricing strategy that reduces risk and fosters shared success in the project.

partner

Reaxense

upacc

P14555

UPID:

PA2GA_HUMAN

Alternative names:

GIIC sPLA2; Group IIA phospholipase A2; Non-pancreatic secretory phospholipase A2; Phosphatidylcholine 2-acylhydrolase 2A

Alternative UPACC:

P14555; A8K5I7; Q6DN24; Q6IBD9; Q9UCD2

Background:

Phospholipase A2, membrane associated (P14555), known as GIIC sPLA2, plays a pivotal role in host defense, inflammation, and tissue regeneration. It targets extracellular phospholipids, favoring phosphatidylethanolamines and phosphatidylglycerols, and is involved in lipid remodeling and generation of lipid mediators for pathogen clearance. Its bactericidal activity against Gram-positive bacteria and role in sterile inflammation highlight its importance in immune response.

Therapeutic significance:

Understanding the role of Phospholipase A2, membrane associated, could open doors to potential therapeutic strategies. Its involvement in lipid remodeling, immune response, and tissue regeneration presents a unique opportunity for developing treatments targeting inflammatory diseases and infections.

Looking for more information on this library or underlying technology? Fill out the form below and we'll be in touch with all the details you need.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.